Develops cannabinoid therapeutics, including a licensed treatment program for neuropsychiatric disorders.
10-K for FY2025, filed Mar 31, 2026
$12.6K
10-K for FY2022, filed Apr 13, 2023
$12.6K ↗
No. It lost $602.2K in FY2021.
10-K for FY2022, filed Apr 13, 2023
10-Q for Q2 FY2026, filed Aug 14, 2026
$611.4KView ↗
8-K, filed Jul 31, 2026
Also effective July 29, 2026, the Board appointed Carlos Septién as the Company’s Chief Operating Officer, Michelle Cervantes Vivanco as…View ↗
8-K, filed Jul 6, 2026
On June 29, 2026, Trafalgar Asset Management, LLC, a Delaware limited liability company owned and controlled by Porfirio Sanchez Talavera…View ↗
Shrinking. Revenue fell 87% in 3 years, from $95.4K in FY2018 to $12.6K in FY2021, about 49% a year.
Narrowed business focus
The older report paired cannabinoid-therapy development with cannabis-related investment and deal opportunities; the latest describes therapeutic development and commercialization and says the company no longer intends direct investment operations.
10-K for FY2022, filed Apr 13, 2023 10-K for FY2025, filed Mar 31, 2026The Company’s business plan is to (i) conduct clinical studies on and commercialize the cannabinoid-based therapeutic and (ii) concentrate…View ↗
After the consummation of the above-described transactions, the Company switched its business model in fiscal 2018 and no longer intended…View ↗
Competes with Jazz Pharmaceuticals and Zynerba Pharmaceuticals
10-K for FY2025, filed Mar 31, 2026There are a number of other companies operating in the cannabis space. Such companies range from producers of cannabis plants to makers of…View ↗
Loading...